- Strategic partnership in Europe extended to cover five additional molecules in therapeutic categories including oncology and diabetes
- Adalvo CEO Anil Okay: “These new agreements demonstrate the significance of the strategic partnership we have built with STADA, in the last couple of years. We take pride in making a difference in people’s lives, by bringing high quality medicines to the market, together with our partner.”
- STADA’s Head of Global Development, Portfolio, Regulatory and Business Development/Licensing, Yann Brun: “Working closely as a trusted partner with Adalvo is central to STADA’s commitment to caring for people’s health by supplying specialty, generic and consumer healthcare medicines.”
Adalvo and STADA have extended their strategic partnership by recently signing licensing deals for five additional molecules. The agreements give STADA commercial rights to the molecules within Europe.
Among the active ingredients covered by recently-signed deals are several molecules for oncology and diabetes, therapeutic categories that are forecast to be among the largest and fastest-growing within the global pharma sector over the coming years. The extension to the long-standing strategic partnership between Adalvo and STADA involves a variety of delivery forms, including difficult-to-make formulations.
The two partners expect the deal to strengthen their position in the generic and value-added medicines sectors, providing patients and their caregivers with high-quality and affordable treatment options.